REHOVOT, Israel, June 14 /PRNewswire/ -- Rosetta Genomics and Rockefeller University today announced the signing of a licensing agreement that will allow Rosetta Genomics to access nearly 180 proprietary microRNAs from Rockefeller University. These microRNAs will be added to Rosetta Genomics's microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs. Under the terms of the agreement, Rosetta Genomics will be able to use these microRNAs to potentially advance multiple research development programs targeting new microRNA based diagnostic tools for a variety of diseases. "Being one of the first companies to focus on microRNAs, we see ourselves as leaders in this field, and our filed patent applications cover more than half of all biologically validated microRNAs of which we are aware. This agreement positions us to apply our experience and expand our development program further in the years ahead. We are now positioned to target a broader range of promising development and commercial opportunities in the microRNA arena," said Amir Avniel, president and CEO of Rosetta Genomics. Rosetta Genomics has developed a proprietary discovery process that has led to the discovery of nearly 360 biologically validated human microRNAs. The agreement with Rockefeller positions Rosetta Genomics to pursue research based on 530 of the 660 publicly-confirmed microRNA genes in the entire human genome. Under the terms of the agreement, Rosetta Genomics will pay an initiation fee to Rockefeller University as well as maintenance fees and royalties. About microRNAs MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to be the basis for a new class of diagnostics and therapeutics. Because many diseases are caused by the misregulated activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. These differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body. The recent discovery of microRNAs is recognized as a major scientific breakthrough that has the potential to transform the diagnosis, prevention and treatment of diseases. About Rockefeller University The Rockefeller University is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, and physics. Founded by John D. Rockefeller in 1901, the university has been the site of many important scientific breakthroughs. Rockefeller scientists established that DNA is the chemical basis of heredity, discovered blood groups, showed that viruses can cause cancer, founded the modern field of cell biology, and worked out the structure of antibodies. Twenty-three Nobel Prize winners have been associated with the university. For more information please visit: http://www.rockefeller.edu About Rosetta Genomics Rosetta Genomics is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of nearly 360 biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostics and therapeutic products based on microRNAs. The company's primary therapeutic focus is in the development of microRNA-based products to diagnose and treat different forms of cancer.
SOURCE Rosetta Genomics